Balancing risks: Dosing strategies for antidepressants near the end of pregnancy

Journal of Clinical Psychiatry

Volumn 69, Issue 2, 2008, Pages 323-324

  Miller, Laura J ^a   Bishop, Jeffrey R ^b   Fischer, James H ^b   Geller, Stacie E ^a   Macmillan, Carol ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; SERTRALINE;

BEHAVIOR DISORDER; CRYING; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG USE; FEMALE; HEART ARRHYTHMIA; HUMAN; IRRITABILITY; MAJOR DEPRESSION; MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; NERVOUSNESS; NEWBORN DISEASE; NYSTAGMUS; PERSISTENT PULMONARY HYPERTENSION; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEIZURE; SHORT SURVEY; SIDE EFFECT; SLEEP DISORDER; THIRD TRIMESTER PREGNANCY; TREMOR; WEAK CRY;

EID: 41549103823     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0220     Document Type: Short Survey

References (24)

1. Gaynes BN, Gavin N, Meltzer-Brody S, et al. Perinatal Depression: Prevalence, Screening Accuracy, and Screening Outcomes. Rockville, Md: Agency for Healthcare Research and Quality; 2005. Evidence Report/Technology Assessment 119
2. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295:499-507
3. Alder J, Fink N, Bitzer J, et al. Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? a critical review of the literature. J Matern Fetal Neonatal Med 2007;20:189-209
4. US Food and Drug Administration. FDA Public Health Advisory: Treatment Challenges of Depression in Pregnancy and the Possibility of Persistent Pulmonary Hypertension in Newborns. Available at: http://www.fda.gov/CDER/DRUG/ advisory/SSRI_PPHN200607.htm. Accessed July 19, 2006
5. Dayan J, Creveuil C, Marks MN, et al. Prenatal depression, prenatal anxiety, and spontaneous preterm birth: a prospective cohort study among women with early and regular care. Psychosom Med 2006;68:938-946
6. Field T, Diego M, Hernandez-Reif M. Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev 2006;29:445-455
7. Zuckerman B, Bauchner H, Parker S, et al. Maternal depressive symptoms during pregnancy, and newborn irritability. J Dev Behav Pediatr 1990;11:190-194
8. Rahman A, Iqbal Z, Bunn J, et al. Impact of maternal depression on infant nutritional status and illness: a cohort study. Arch Gen Psychiatry 2004;61:946-952
9. Huot RL, Brennan PA, Stowe ZN, et al. Negative affect in offspring of depressed mothers is predicted by infant cortisol levels at 6 months and maternal depression during pregnancy, but not postpartum. Ann N Y Acad Sci 2004;1032:234-236
10. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004;113:368-375
11. Cohen LS, Heller VL, Bailey JW, et al. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000;48:996-1000
12. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004;158:312-316
13. Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-1132
14. Oberlander TF, Misri S, Fitzgerald CE, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004;65:230-237
15. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005;365:482-487
16. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160:173-176
17. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotoninreuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-587
18. Frederiksen MC. Physiologic changes in pregnancy and their effect on drug disposition. Semin Perinatol 2001;25:120-123
19. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005;44:989-1008
20. Wadelius M, Darj E, Frenne G, et al. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 1997;62:400-407
21. Tsutsumi K, Kotegawa T, Matsuki S, et al. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans. Clin Pharmacol Ther 2001;70:121-125
22. Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6, and CYP3A activity) during pregnancy. Am J Obstet Gynecol 2005;192:633-639
23. Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003;73:330-337
24. Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002;72:184-191